Avalyn Pharma Adds $100M Series D for Inhaled Pulmonary Fibrosis Drugs
The company is pushing inhaled versions of common oral drugs with the hope of avoiding severe side effects.
Avalyn Pharma Adds $100M Series D for Inhaled Pulmonary Fibrosis Drugs Read More »
